Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS Pasithea Tx (Nasdaq: KTTA) Selects Lead Development Candidate, Humanized mAb that Targets α5β1 Integrin for Treatment of both Sporadic and Familial ALS

Amyotrophic Lateral Sclerosis Treatment Market to Reach US$ 594.1 Million in 2031, Expanding at a CAGR of 5.5%: TMR Report Wilmington, Delaware, United States, June 26, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. – In 2022, the global industry was estimated to be worth $594.1 million. It is expected to...

Amyotrophic Lateral Sclerosis Treatment Market Sales to Reach US$ 1021 Million in 2032 | CAGR of 5.6% New York, April 14, 2023 (GLOBE NEWSWIRE) -- The global Amyotrophic Lateral Sclerosis Treatment Market was valued at US$ 600 million in 2022 and is expected to grow US$ 1021 million in 2032. Between...